CTY

20.36010.95%
JM

John Michael Maraganore

Independent External Director

Dr. John Michael Maraganore, Ph.D., M.D., serves as a Strategic Advisor at NYBC Ventures since October 2026. He is a Co-Founder and Executive Chair of City Therapeutics, Inc. since September 2023. He is Co-Founder, President, Co-CEO and Director of Corsera Health, Inc. He is Principal of JMM Innovations. He is Director at Brixton Biosciences, Inc. since August 2026. He is Senior Advisor of General Atlantic Service Company, L.P. He focuses on Life Sciences. He is Advisor of Energy Capital Partners, LLC since 2026. He is Director of Archemix Corp. since May 2006 and joined Archemix Corp. in May 2006. He is Senior Advisor of Blackstone Life Sciences. He is Independent External Director of Takeda Pharmaceutical Company Limited from June 29, 2022, and joined Takeda Pharmaceutical Company Limited in June 2022. He is Member of the Scientific Advisory Board of ai3Bio, Inc. He is Member of the Strategic Advisory Board of Legend Biotech Corporation from April 2023, Member of the Strategic Advisory Board of Codexis, Inc. from February 2024, Member of the Biopharma Advisory Board of Ginkgo Bioworks Holdings, Inc. from January 08, 2024, Member of the Executive Advisory Board of SalioGen Therapeutics, Inc. from November 2021, Member of the Advisory Board of Abata Therapeutics, Inc. from April 2022, Member of the Scientific Advisory Board of Totus Medicines, Inc. from October 2023, and Member of the Strategic Advisory Board of Hybridize Therapeutics B.V. He is Venture Partner of ARCH Venture Partners, L.P. from December 01, 2021, and joined ARCH Venture Partners, L.P. on December 01, 2021. He is Venture Advisor of Atlas Venture Advisors, Inc. He is Independent Director of Kymera Therapeutics, Inc. from January 2022 and joined Kymera Therapeutics, Inc. in January 2022. He is Independent Director of Beam Therapeutics Inc. from November 05, 2021. He is Board Member of Tevard Biosciences, Inc. from 2025, Member of the Strategic Advisory Board of Terray Therapeutics, Inc. from 2026, Director of Axion Bio, Inc., Strategic Advisor of Instil Bio, Inc. from June 2025, Executive Strategic Advisor to the CEO and Director of Lipidio Pharmaceuticals Inc. from 2022, Director of Protego Biopharma, Inc. from March 2026, Chairman of Hemab ApS from January 2022, Senior Advisor and Observer of Mahzi Therapeutics, Inc., Advisor of Judo Bio Inc., Co-Founder and Chairman of Orbital Therapeutics, Inc., Chairman of the Board of Aera Therapeutics Inc., Independent Director of Rapport Therapeutics, Inc. from March 2024, Director of GEMMA Biotherapeutics, Inc., Director of Merida Biosciences, Inc., Independent Chairman of Hemab Therapeutics Holdings, Inc. from January 2022, and External Director of Takeda Ventures, Inc. from June 2026. He was founding CEO and a Director of Alnylam Pharmaceuticals, Inc. from 2002 to 2021, joined Alnylam Pharmaceuticals, Inc. in December 2002, served as CEO and Executive Director from December 2012 to December 31, 2021, and was a Member of its Scientific Advisory Board from December 31, 2021. At Alnylam Pharmaceuticals, Inc., he built the company from early platform research on RNAi through commercialization of ONPATTRO, GIVLAARI, OXLUMO, LEQVIO, and AMVUTTRA. He previously served as Senior Vice President of Strategic Product Development of Millennium Pharmaceuticals, Inc., Executive Officer of Biogen Inc., and a scientist at ZymoGenetics and The Upjohn Company. He was Venture Partner of Third Rock Ventures, LLC and joined Third Rock Ventures, LLC on May 14, 2013. He was Director of MacroGenics, Inc. from October 2006 to June 2009, Director of Agios Pharmaceuticals, Inc. from February 01, 2019 to May 25, 2023, Chairman of the Board of Agios Pharmaceuticals, Inc. from November 2011 to February 01, 2019, Lead Independent Director of Agios Pharmaceuticals, Inc. until May 25, 2023, Board Advisor of CytomX Therapeutics, Inc., Director of Genetix Biotherapeutics, Inc. from January 2012 to September 20, 2017, Director of Regulus Therapeutics Inc. from January 2009 to June 11, 2013, Chairman of the Board of GNS Healthcare, Inc. from 2022 to October 2025, Director of Taligen Therapeutics, Inc. and joined Taligen Therapeutics, Inc. in April 2010, Board Advisor of Proclara Biosciences, Inc. and joined Proclara Biosciences, Inc. in 2009, Independent Director of ProKidney Corp. from May 2022 to June 2024, and Director of Versanis Bio, Inc. from July 2022. He also served as Director of Tempero Pharmaceuticals, Inc. and Chroma Medicine, Inc. He received a Ph.D. in Biochemistry and Molecular Biology, an M.S. in Biochemistry and Molecular Biology, and a B.A. in Biological Sciences from The University of Chicago.

Positions